A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO‐idel)
Summary Idelalisib (IDL) is an oral first‐in‐class phosphatidylinositol 3‐kinase delta (PI3Kδ) inhibitor approved for chronic lymphocytic leukaemia (CLL) alongside rituximab (R) since 2014. However, little data exist on routine practice. The RETRO‐idel was a protocol‐led, retrospective study of 110...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2021-07, Vol.194 (1), p.69-77 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 77 |
|---|---|
| container_issue | 1 |
| container_start_page | 69 |
| container_title | British journal of haematology |
| container_volume | 194 |
| creator | Eyre, Toby A. Preston, Gavin Kagdi, Huseini Islam, Amin Nicholson, Toby Smith, Harry W. Cursley, Adam P. Ramroth, Heribert Xing, Guan Gu, Lin Rajakumaraswamy, Nishanthan Fegan, Christopher |
| description | Summary
Idelalisib (IDL) is an oral first‐in‐class phosphatidylinositol 3‐kinase delta (PI3Kδ) inhibitor approved for chronic lymphocytic leukaemia (CLL) alongside rituximab (R) since 2014. However, little data exist on routine practice. The RETRO‐idel was a protocol‐led, retrospective study of 110 patients [n = 27 front‐line (1L)] who received IDL‐R. The primary end‐point was clinical overall response rate (ORR). The median (range) follow‐up of the whole cohort was 30·2 (0·1–51·9) months. The median (range) age was 72 (48–89) years. Tumour protein p53‐disruption was common [100% 1L, 32·5% relapsed/refractory (R/R)]. The best ORR (intention‐to‐treat) was 88·2% (1L 96·3%, R/R 85·5%). Overall, the median event‐free survival (mEFS) was 20·3 months and time‐to‐next treatment was 29·2 months. The mEFS for 1L patients was 18·7 months and R/R patients was 21·7 months. The 3‐year overall survival was 56·1% (95% confidence interval 45·7–65·3). IDL was discontinued in 87·3% (n = 96). More patients discontinued due to adverse events in the front‐line setting (1L 63·0% vs. R/R 44·6%) and due to progressive disease in R/R patients (20·5% vs. 3·7% in 1L). Lower respiratory tract infection/pneumonia were reported in 34·5% (Grade ≥3, 19·1%), diarrhoea in 30·9% (Grade ≥3, 6·4%), and colitis in 9·1% (Grade ≥3, 5·5%). Overall, these data describe clear efficacy for IDL‐R in routine practice. No new safety signals were identified, although careful management of known toxicities is required. |
| doi_str_mv | 10.1111/bjh.17475 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8361941</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2540723186</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4435-d579c57d6b1d312069ff3464ad827f7e40b9e800ef547e1c6be051d5075df9ad3</originalsourceid><addsrcrecordid>eNp1ksFu1DAQhiMEokvhwAsgS1zaQ1o7sePkglSqlhYqVaras-XYk8ZLEm9tZ0tuPEKfjgfgSfBuSgVI-DJj-5vfM55JkrcEH5C4Dutle0A45exZsiB5wdKMUPI8WWCMeUowLXeSV94vMSY5ZuRlspNTkhFS0kXy4wg5CM76Fahg1oBs7cGtZTB2kB3yYdQTChbBWnajDIBCC0h1ZjAqXtsxKNuDR3LQyMWdGQD1cpC30MMQkG3QKkpF16N7E1qkWmdjKOqmftVaNYWND-NXCb2RKDiIT-gZNRo62Rlv6lndhPGb6WWNzLBN4ubL9vzcRSzavauT66vLn98fNnH7r5MXjew8vHm0u8nN6cn18Vl6cfnp_PjoIlWU5izVjFeKcV3UROckw0XVNDktqNRlxhsOFNcVlBhDwygHoooa4gdqhjnTTSV1vpt8mHVXY92DVrFSJzuxcjFTNwkrjfj7ZjCtuLVrUeYFqSiJAnuPAs7ejeCD6I1X0MWawI5eZIxinuWkLCL6_h90aUcXu7SlWMWzsiojtT9TKjbVO2iekiFYbKZFxGkR22mJ7Ls_s38if49HBA5n4N50MP1fSXz8fDZL_gKkt8_X</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2545972898</pqid></control><display><type>article</type><title>A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO‐idel)</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><creator>Eyre, Toby A. ; Preston, Gavin ; Kagdi, Huseini ; Islam, Amin ; Nicholson, Toby ; Smith, Harry W. ; Cursley, Adam P. ; Ramroth, Heribert ; Xing, Guan ; Gu, Lin ; Rajakumaraswamy, Nishanthan ; Fegan, Christopher</creator><creatorcontrib>Eyre, Toby A. ; Preston, Gavin ; Kagdi, Huseini ; Islam, Amin ; Nicholson, Toby ; Smith, Harry W. ; Cursley, Adam P. ; Ramroth, Heribert ; Xing, Guan ; Gu, Lin ; Rajakumaraswamy, Nishanthan ; Fegan, Christopher</creatorcontrib><description>Summary
Idelalisib (IDL) is an oral first‐in‐class phosphatidylinositol 3‐kinase delta (PI3Kδ) inhibitor approved for chronic lymphocytic leukaemia (CLL) alongside rituximab (R) since 2014. However, little data exist on routine practice. The RETRO‐idel was a protocol‐led, retrospective study of 110 patients [n = 27 front‐line (1L)] who received IDL‐R. The primary end‐point was clinical overall response rate (ORR). The median (range) follow‐up of the whole cohort was 30·2 (0·1–51·9) months. The median (range) age was 72 (48–89) years. Tumour protein p53‐disruption was common [100% 1L, 32·5% relapsed/refractory (R/R)]. The best ORR (intention‐to‐treat) was 88·2% (1L 96·3%, R/R 85·5%). Overall, the median event‐free survival (mEFS) was 20·3 months and time‐to‐next treatment was 29·2 months. The mEFS for 1L patients was 18·7 months and R/R patients was 21·7 months. The 3‐year overall survival was 56·1% (95% confidence interval 45·7–65·3). IDL was discontinued in 87·3% (n = 96). More patients discontinued due to adverse events in the front‐line setting (1L 63·0% vs. R/R 44·6%) and due to progressive disease in R/R patients (20·5% vs. 3·7% in 1L). Lower respiratory tract infection/pneumonia were reported in 34·5% (Grade ≥3, 19·1%), diarrhoea in 30·9% (Grade ≥3, 6·4%), and colitis in 9·1% (Grade ≥3, 5·5%). Overall, these data describe clear efficacy for IDL‐R in routine practice. No new safety signals were identified, although careful management of known toxicities is required.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.17475</identifier><identifier>PMID: 34121184</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Adverse events ; Aged ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; B‐cell receptor inhibitor ; chronic lymphocytic leukaemia ; Chronic lymphocytic leukemia ; Colitis ; Diarrhea ; Enzyme inhibitors ; Female ; Gastrointestinal Diseases - chemically induced ; Haematological malignancy ‐ Clinical ; Hematologic Diseases - chemically induced ; Hematology ; Humans ; idelalisib ; Ireland - epidemiology ; Kaplan-Meier Estimate ; Kinases ; Leukemia ; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell - epidemiology ; Male ; Middle Aged ; Observational studies ; p53 Protein ; Patients ; Phosphoinositide-3 Kinase Inhibitors - administration & dosage ; PI3K ; Progression-Free Survival ; Purines - administration & dosage ; Purines - adverse effects ; Quinazolinones - administration & dosage ; Quinazolinones - adverse effects ; Research Paper ; Respiratory tract diseases ; Respiratory Tract Diseases - chemically induced ; retrospective ; Retrospective Studies ; Rituximab ; Rituximab - administration & dosage ; Rituximab - adverse effects ; Salvage Therapy ; Survival ; Treatment Outcome ; Tumors ; United Kingdom - epidemiology</subject><ispartof>British journal of haematology, 2021-07, Vol.194 (1), p.69-77</ispartof><rights>2021 Gilead Sciences Ltd. published by John Wiley & Sons Ltd and British Society for Haematology.</rights><rights>2021 Gilead Sciences Ltd. British Journal of Haematology published by John Wiley & Sons Ltd and British Society for Haematology.</rights><rights>2021. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4435-d579c57d6b1d312069ff3464ad827f7e40b9e800ef547e1c6be051d5075df9ad3</citedby><cites>FETCH-LOGICAL-c4435-d579c57d6b1d312069ff3464ad827f7e40b9e800ef547e1c6be051d5075df9ad3</cites><orcidid>0000-0002-6631-9749 ; 0000-0002-0575-8844 ; 0000-0001-9685-0621</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjh.17475$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjh.17475$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34121184$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Eyre, Toby A.</creatorcontrib><creatorcontrib>Preston, Gavin</creatorcontrib><creatorcontrib>Kagdi, Huseini</creatorcontrib><creatorcontrib>Islam, Amin</creatorcontrib><creatorcontrib>Nicholson, Toby</creatorcontrib><creatorcontrib>Smith, Harry W.</creatorcontrib><creatorcontrib>Cursley, Adam P.</creatorcontrib><creatorcontrib>Ramroth, Heribert</creatorcontrib><creatorcontrib>Xing, Guan</creatorcontrib><creatorcontrib>Gu, Lin</creatorcontrib><creatorcontrib>Rajakumaraswamy, Nishanthan</creatorcontrib><creatorcontrib>Fegan, Christopher</creatorcontrib><title>A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO‐idel)</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary
Idelalisib (IDL) is an oral first‐in‐class phosphatidylinositol 3‐kinase delta (PI3Kδ) inhibitor approved for chronic lymphocytic leukaemia (CLL) alongside rituximab (R) since 2014. However, little data exist on routine practice. The RETRO‐idel was a protocol‐led, retrospective study of 110 patients [n = 27 front‐line (1L)] who received IDL‐R. The primary end‐point was clinical overall response rate (ORR). The median (range) follow‐up of the whole cohort was 30·2 (0·1–51·9) months. The median (range) age was 72 (48–89) years. Tumour protein p53‐disruption was common [100% 1L, 32·5% relapsed/refractory (R/R)]. The best ORR (intention‐to‐treat) was 88·2% (1L 96·3%, R/R 85·5%). Overall, the median event‐free survival (mEFS) was 20·3 months and time‐to‐next treatment was 29·2 months. The mEFS for 1L patients was 18·7 months and R/R patients was 21·7 months. The 3‐year overall survival was 56·1% (95% confidence interval 45·7–65·3). IDL was discontinued in 87·3% (n = 96). More patients discontinued due to adverse events in the front‐line setting (1L 63·0% vs. R/R 44·6%) and due to progressive disease in R/R patients (20·5% vs. 3·7% in 1L). Lower respiratory tract infection/pneumonia were reported in 34·5% (Grade ≥3, 19·1%), diarrhoea in 30·9% (Grade ≥3, 6·4%), and colitis in 9·1% (Grade ≥3, 5·5%). Overall, these data describe clear efficacy for IDL‐R in routine practice. No new safety signals were identified, although careful management of known toxicities is required.</description><subject>Adverse events</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>B‐cell receptor inhibitor</subject><subject>chronic lymphocytic leukaemia</subject><subject>Chronic lymphocytic leukemia</subject><subject>Colitis</subject><subject>Diarrhea</subject><subject>Enzyme inhibitors</subject><subject>Female</subject><subject>Gastrointestinal Diseases - chemically induced</subject><subject>Haematological malignancy ‐ Clinical</subject><subject>Hematologic Diseases - chemically induced</subject><subject>Hematology</subject><subject>Humans</subject><subject>idelalisib</subject><subject>Ireland - epidemiology</subject><subject>Kaplan-Meier Estimate</subject><subject>Kinases</subject><subject>Leukemia</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - epidemiology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Observational studies</subject><subject>p53 Protein</subject><subject>Patients</subject><subject>Phosphoinositide-3 Kinase Inhibitors - administration & dosage</subject><subject>PI3K</subject><subject>Progression-Free Survival</subject><subject>Purines - administration & dosage</subject><subject>Purines - adverse effects</subject><subject>Quinazolinones - administration & dosage</subject><subject>Quinazolinones - adverse effects</subject><subject>Research Paper</subject><subject>Respiratory tract diseases</subject><subject>Respiratory Tract Diseases - chemically induced</subject><subject>retrospective</subject><subject>Retrospective Studies</subject><subject>Rituximab</subject><subject>Rituximab - administration & dosage</subject><subject>Rituximab - adverse effects</subject><subject>Salvage Therapy</subject><subject>Survival</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>United Kingdom - epidemiology</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp1ksFu1DAQhiMEokvhwAsgS1zaQ1o7sePkglSqlhYqVaras-XYk8ZLEm9tZ0tuPEKfjgfgSfBuSgVI-DJj-5vfM55JkrcEH5C4Dutle0A45exZsiB5wdKMUPI8WWCMeUowLXeSV94vMSY5ZuRlspNTkhFS0kXy4wg5CM76Fahg1oBs7cGtZTB2kB3yYdQTChbBWnajDIBCC0h1ZjAqXtsxKNuDR3LQyMWdGQD1cpC30MMQkG3QKkpF16N7E1qkWmdjKOqmftVaNYWND-NXCb2RKDiIT-gZNRo62Rlv6lndhPGb6WWNzLBN4ubL9vzcRSzavauT66vLn98fNnH7r5MXjew8vHm0u8nN6cn18Vl6cfnp_PjoIlWU5izVjFeKcV3UROckw0XVNDktqNRlxhsOFNcVlBhDwygHoooa4gdqhjnTTSV1vpt8mHVXY92DVrFSJzuxcjFTNwkrjfj7ZjCtuLVrUeYFqSiJAnuPAs7ejeCD6I1X0MWawI5eZIxinuWkLCL6_h90aUcXu7SlWMWzsiojtT9TKjbVO2iekiFYbKZFxGkR22mJ7Ls_s38if49HBA5n4N50MP1fSXz8fDZL_gKkt8_X</recordid><startdate>202107</startdate><enddate>202107</enddate><creator>Eyre, Toby A.</creator><creator>Preston, Gavin</creator><creator>Kagdi, Huseini</creator><creator>Islam, Amin</creator><creator>Nicholson, Toby</creator><creator>Smith, Harry W.</creator><creator>Cursley, Adam P.</creator><creator>Ramroth, Heribert</creator><creator>Xing, Guan</creator><creator>Gu, Lin</creator><creator>Rajakumaraswamy, Nishanthan</creator><creator>Fegan, Christopher</creator><general>Blackwell Publishing Ltd</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6631-9749</orcidid><orcidid>https://orcid.org/0000-0002-0575-8844</orcidid><orcidid>https://orcid.org/0000-0001-9685-0621</orcidid></search><sort><creationdate>202107</creationdate><title>A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO‐idel)</title><author>Eyre, Toby A. ; Preston, Gavin ; Kagdi, Huseini ; Islam, Amin ; Nicholson, Toby ; Smith, Harry W. ; Cursley, Adam P. ; Ramroth, Heribert ; Xing, Guan ; Gu, Lin ; Rajakumaraswamy, Nishanthan ; Fegan, Christopher</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4435-d579c57d6b1d312069ff3464ad827f7e40b9e800ef547e1c6be051d5075df9ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adverse events</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>B‐cell receptor inhibitor</topic><topic>chronic lymphocytic leukaemia</topic><topic>Chronic lymphocytic leukemia</topic><topic>Colitis</topic><topic>Diarrhea</topic><topic>Enzyme inhibitors</topic><topic>Female</topic><topic>Gastrointestinal Diseases - chemically induced</topic><topic>Haematological malignancy ‐ Clinical</topic><topic>Hematologic Diseases - chemically induced</topic><topic>Hematology</topic><topic>Humans</topic><topic>idelalisib</topic><topic>Ireland - epidemiology</topic><topic>Kaplan-Meier Estimate</topic><topic>Kinases</topic><topic>Leukemia</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - epidemiology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Observational studies</topic><topic>p53 Protein</topic><topic>Patients</topic><topic>Phosphoinositide-3 Kinase Inhibitors - administration & dosage</topic><topic>PI3K</topic><topic>Progression-Free Survival</topic><topic>Purines - administration & dosage</topic><topic>Purines - adverse effects</topic><topic>Quinazolinones - administration & dosage</topic><topic>Quinazolinones - adverse effects</topic><topic>Research Paper</topic><topic>Respiratory tract diseases</topic><topic>Respiratory Tract Diseases - chemically induced</topic><topic>retrospective</topic><topic>Retrospective Studies</topic><topic>Rituximab</topic><topic>Rituximab - administration & dosage</topic><topic>Rituximab - adverse effects</topic><topic>Salvage Therapy</topic><topic>Survival</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>United Kingdom - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eyre, Toby A.</creatorcontrib><creatorcontrib>Preston, Gavin</creatorcontrib><creatorcontrib>Kagdi, Huseini</creatorcontrib><creatorcontrib>Islam, Amin</creatorcontrib><creatorcontrib>Nicholson, Toby</creatorcontrib><creatorcontrib>Smith, Harry W.</creatorcontrib><creatorcontrib>Cursley, Adam P.</creatorcontrib><creatorcontrib>Ramroth, Heribert</creatorcontrib><creatorcontrib>Xing, Guan</creatorcontrib><creatorcontrib>Gu, Lin</creatorcontrib><creatorcontrib>Rajakumaraswamy, Nishanthan</creatorcontrib><creatorcontrib>Fegan, Christopher</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eyre, Toby A.</au><au>Preston, Gavin</au><au>Kagdi, Huseini</au><au>Islam, Amin</au><au>Nicholson, Toby</au><au>Smith, Harry W.</au><au>Cursley, Adam P.</au><au>Ramroth, Heribert</au><au>Xing, Guan</au><au>Gu, Lin</au><au>Rajakumaraswamy, Nishanthan</au><au>Fegan, Christopher</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO‐idel)</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2021-07</date><risdate>2021</risdate><volume>194</volume><issue>1</issue><spage>69</spage><epage>77</epage><pages>69-77</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><abstract>Summary
Idelalisib (IDL) is an oral first‐in‐class phosphatidylinositol 3‐kinase delta (PI3Kδ) inhibitor approved for chronic lymphocytic leukaemia (CLL) alongside rituximab (R) since 2014. However, little data exist on routine practice. The RETRO‐idel was a protocol‐led, retrospective study of 110 patients [n = 27 front‐line (1L)] who received IDL‐R. The primary end‐point was clinical overall response rate (ORR). The median (range) follow‐up of the whole cohort was 30·2 (0·1–51·9) months. The median (range) age was 72 (48–89) years. Tumour protein p53‐disruption was common [100% 1L, 32·5% relapsed/refractory (R/R)]. The best ORR (intention‐to‐treat) was 88·2% (1L 96·3%, R/R 85·5%). Overall, the median event‐free survival (mEFS) was 20·3 months and time‐to‐next treatment was 29·2 months. The mEFS for 1L patients was 18·7 months and R/R patients was 21·7 months. The 3‐year overall survival was 56·1% (95% confidence interval 45·7–65·3). IDL was discontinued in 87·3% (n = 96). More patients discontinued due to adverse events in the front‐line setting (1L 63·0% vs. R/R 44·6%) and due to progressive disease in R/R patients (20·5% vs. 3·7% in 1L). Lower respiratory tract infection/pneumonia were reported in 34·5% (Grade ≥3, 19·1%), diarrhoea in 30·9% (Grade ≥3, 6·4%), and colitis in 9·1% (Grade ≥3, 5·5%). Overall, these data describe clear efficacy for IDL‐R in routine practice. No new safety signals were identified, although careful management of known toxicities is required.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>34121184</pmid><doi>10.1111/bjh.17475</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-6631-9749</orcidid><orcidid>https://orcid.org/0000-0002-0575-8844</orcidid><orcidid>https://orcid.org/0000-0001-9685-0621</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2021-07, Vol.194 (1), p.69-77 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8361941 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content |
| subjects | Adverse events Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use B‐cell receptor inhibitor chronic lymphocytic leukaemia Chronic lymphocytic leukemia Colitis Diarrhea Enzyme inhibitors Female Gastrointestinal Diseases - chemically induced Haematological malignancy ‐ Clinical Hematologic Diseases - chemically induced Hematology Humans idelalisib Ireland - epidemiology Kaplan-Meier Estimate Kinases Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - epidemiology Male Middle Aged Observational studies p53 Protein Patients Phosphoinositide-3 Kinase Inhibitors - administration & dosage PI3K Progression-Free Survival Purines - administration & dosage Purines - adverse effects Quinazolinones - administration & dosage Quinazolinones - adverse effects Research Paper Respiratory tract diseases Respiratory Tract Diseases - chemically induced retrospective Retrospective Studies Rituximab Rituximab - administration & dosage Rituximab - adverse effects Salvage Therapy Survival Treatment Outcome Tumors United Kingdom - epidemiology |
| title | A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO‐idel) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T05%3A08%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20retrospective%20observational%20study%20to%20evaluate%20the%20clinical%20outcomes%20and%20routine%20management%20of%20patients%20with%20chronic%20lymphocytic%20leukaemia%20treated%20with%20idelalisib%20and%20rituximab%20in%20the%20UK%20and%20Ireland%20(RETRO%E2%80%90idel)&rft.jtitle=British%20journal%20of%20haematology&rft.au=Eyre,%20Toby%20A.&rft.date=2021-07&rft.volume=194&rft.issue=1&rft.spage=69&rft.epage=77&rft.pages=69-77&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.17475&rft_dat=%3Cproquest_pubme%3E2540723186%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2545972898&rft_id=info:pmid/34121184&rfr_iscdi=true |